Saurashtra News

Myelofibrosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Myelofibrosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 14
01:04 2023
Myelofibrosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Myelofibrosis pipeline constitutes 45+ key companies continuously working towards developing 45+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Myelofibrosis Overview

Myelofibrosis is a rare disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Itis classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Overtime, this leads to progressive bone marrow failure.

 

Myelofibrosis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

 

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Myelofibrosis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years. Myelofibrosis Key players such as – Incyte Corporation, Samus Therapeutics, Sumitomo Pharma Oncology, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others, are developing therapies for the Myelofibrosis treatment 
  • Myelofibrosis Emerging therapies such as – INCB057643, PU-H71, TP-3654, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.   
  • In April 2021, Geron Corporation initiated a randomized open-label, Phase III study to evaluate Imetelstat (GRN163L) versus Best Available Therapy (BAT) in patients with intermediate-2 or high-risk Myelofibrosis(MF) Refractory to Janus Kinase (JAK)-Inhibitor

 

Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Myelofibrosis Pipeline Therapeutics Assessment

  • Myelofibrosis Assessment by Product Type
  • Myelofibrosis By Stage and Product Type
  • Myelofibrosis Assessment by Route of Administration
  • Myelofibrosis By Stage and Route of Administration
  • Myelofibrosis Assessment by Molecule Type
  • Myelofibrosis by Stage and Molecule Type

 

DelveInsight’s Myelofibrosis Report covers around 45+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Myelofibrosis Therapeutics Market include:

Key Companies developing therapies for the Myelofibrosis treatment are – Geron Corporation, AbbVie, Sierra Oncology, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Karyopharm Therapeutics, Incyte Corporation, Bristol Myers Squibb, MorphoSys, Imago BioSciences, Roche, and others

 

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:

  • INCB057643: Incyte Corporation
  • PU-H71: Samus Therapeutics
  • TP-3654: Sumitomo Pharma Oncology
  • KER-050: Keros Therapeutics
  • NS-018: Nippon Shinyaku
  • Parsaclisib: Incyte Corporation
  • Pelabresib: MorphoSys
  • Imetelstat: Geron Corporation

 

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

 

Myelofibrosis Pipeline Analysis:

The Myelofibrosis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
  • Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies

 

Myelofibrosis Pipeline Market Drivers

  • Increase in R&D for the development of new and effective drug for the treatment

 

Myelofibrosis Pipeline Market Barriers

  • Lack of disease modifying agents or Treatments
  • High cost of therapy

 

Scope of Myelofibrosis Pipeline Drug Insight    

  • Coverage: Global
  • Key Myelofibrosis Companies: Incyte Corporation, Samus Therapeutics, Sumitomo Pharma Oncology, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, and others
  • Key Myelofibrosis Therapies: INCB057643, PU-H71, TP-3654, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, and others
  • Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
  • Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers 

 

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials

 

Table of Contents

1

Myelofibrosis Report Introduction

2

Myelofibrosis Executive Summary

3

Myelofibrosis Overview

4

Myelofibrosis- Analytical Perspective In-depth Commercial Assessment

5

Myelofibrosis Pipeline Therapeutics

6

Myelofibrosis Late Stage Products (Phase II/III)

7

Myelofibrosis Mid Stage Products (Phase II)

8

Myelofibrosis Early Stage Products (Phase I)

9

Myelofibrosis Preclinical Stage Products

10

Myelofibrosis Therapeutics Assessment

11

Myelofibrosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Myelofibrosis Key Companies

14

Myelofibrosis Key Products

15

Myelofibrosis Unmet Needs

16 

Myelofibrosis Market Drivers and Barriers

17

Myelofibrosis Future Perspectives and Conclusion

18

Myelofibrosis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com